EXHIBIT 2

Document 25-3

06/18/2004

Page 2 of 4

Case 1:04-md-01592-MLW

///

///

///

///

///

///

///

///

The Court has before it a request for a status conference from defendant and counterclaimant, The Trustees of Columbia University in the City of New York ("Columbia") (filed March 19, 2004). Columbia suggests that the Court conducts status conference to consider staying discovery in this matter pending a ruling by the Judicial Panel on Multidistrict Litigation (the "MDL Panel") on Columbia's petition for consolidated pre-trial proceedings.

The Court also has before it, from plaintiffs and counterdefendants Immunex Corporation and Amgen, Inc. (collectively, "Amgen"), an *Ex Parte* Application For Order (i) To Require Columbia To Comply With Its Rule 26 Obligations, (ii) That Formal Discovery May Commence, and (iii) That Amgen's Written Discovery Is Timely, Valid and Proper (the "*Ex Parte* Application).

The Court conducted a telephonic conference with counsel for all parties on March 22, 2004. Amgen was represented at the hearing by Arthur Wineburg and Jennie L. La Prade of Pillsbury Winthrop. Columbia was represented by Wayne Barsky of Gibson, Dunn & Crutcher.

The Court finds that, in view of Columbia's pending petition before the MDL Panel, oral argument on which is set for March 23, 2004, there is good cause to stay discovery in this action. Accordingly, the Court ORDERS as follows:

1. All discovery in this action shall be held in abeyance pending a ruling by the MDL Panel on Columbia's pending petition for consolidated pre-trial proceedings.

United States District Judge